GSK profit beats on Shingrix, demand for pain meds during pandemic

(Reuters) - GlaxoSmithKline's first-quarter profit beat analysts' expectations on Wednesday due to strong demand for its blockbuster shingles vaccine and higher sales of some of its pain relief medicines during the coronavirus pandemic.Like its rival AstraZeneca , the British drugmaker stuck to its 2020 forecast and still expects a 1% to 4% fall in profit for the year.Turnover rose 19% to 9.09 billion pounds in the three months ended March 31 from a year earlier, while adjusted earnings were..